KM
Kennen MacKay RBC Capital Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Nuvation Bio
NUVB
$1.15B
| $3.35 | $5 |
49%
upside
| Outperform |
17 Apr ‘24
1 year ago |
|
2
Agios Pharmaceuticals
AGIO
$2.11B
| $36.34 | $42 |
16%
upside
| Outperform |
27 Jun ‘23
2 years ago |
|
3
Amgen
AMGN
$151B
| $281.25 | $236 |
16%
downside
| Sector Perform |
5 Aug ‘22
3 years ago |
|
4
Exelixis
EXEL
$10.2B
| $37.88 | $31 |
18%
downside
| Outperform |
3 Nov ‘21
3 years ago |
|
5
ADC Therapeutics
ADCT
$379M
| $3.37 | $34 |
909%
upside
| Outperform |
3 Nov ‘21
3 years ago |
|
|
ATYR
6
aTyr Pharma
ATYR
$546M
| $5.57 | $22 |
295%
upside
| Outperform |
12 Oct ‘21
3 years ago |
|
7
Prothena Corp
PRTA
$437M
| $8.11 | $82 |
911%
upside
| Outperform |
30 Sep ‘21
4 years ago |
|
8
Puma Biotechnology
PBYI
$235M
| $4.67 | $6 |
28%
upside
| Sector Perform |
6 Aug ‘21
4 years ago |
|
9
BioMarin Pharmaceuticals
BMRN
$10.7B
| $55.64 | $88 |
58%
upside
| Sector Perform |
29 Jul ‘21
4 years ago |
|
10
Nurix Therapeutics
NRIX
$690M
| $9.02 | $42 |
366%
upside
| Outperform |
30 Apr ‘21
4 years ago |
|
|
MESO
11
Mesoblast
MESO
$1.89B
| $14.79 | $48 |
225%
upside
| Sector Perform |
22 Oct ‘20
4 years ago |
|
12
Abeona Therapeutics
ABEO
$347M
| $6.77 | $175 |
2,485%
upside
| Outperform |
8 May ‘20
5 years ago |
|